Cardiac stem cells for cardiac repair
AssigneeUniversity of Maryland, Baltimore
InventorSunjay KAUSHAL
Life of this patent
Estimating the term…
Abstract
Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to a subject in need thereof.
Claims26
A composition, comprising neonatal cardiac cells which have been manipulated to increase expression of SDF-1α, VEGF-A, PGDF-B, IL-6, FGF-2, or combinations thereof, and wherein the neonatal cardiac cells are
- (a) positive for protein expression of c-kit and Nkx2.5,
- (b) negative for protein expression of ISL1;
- and
- (c) negative for protein expression of CD31, CD106, CD140b, or CD86.
A composition comprising human, neonatal cardiac stem cells and one or more pharmaceutically acceptable carriers, wherein the human, neonatal cardiac stem cells:
- (a) positive for protein expression of c-kit, SDF-1α, VEGF-A, PGDF-B, IL-6, FGF-2, and Nkx2.5,
- (b) negative for protein expression of ISL1;
- and
- (c) negative for protein expression of CD31, CD106, CD140b, or CD86.
A method of treating a cardiac medical condition in a subject in need thereof, comprising administering to the subject a composition comprising human, neonatal cardiac stem cells and one or more pharmaceutically acceptable carriers, wherein the human, neonatal cardiac stem cells:
- (a) positive for protein expression of c-kit, SDF-1α, VEGF-A, PGDF-B, IL-6, FGF-2, and Nkx2.5,
- (b) negative for protein expression of ISL1;
- and
- (c) negative for protein expression of CD31, CD106, CD140b, or CD86,
- whereby the cardiac medical condition is treated.
A composition comprising genetically engineered, human, neonatal cardiac stem cells and one or more pharmaceutically acceptable carriers, wherein the genetically engineered, human, neonatal cardiac stem cells:
- (a) are positive for protein expression of c-kit and Nkx2.5,
- (b) negative for protein expression of GATA4, CD31, and Isl1, and
- (c) comprise an exogenous nucleic acid construct that encodes SDF-1α, VEGF-A, PDGF-A, IL-6, or FGF-2.
A pharmaceutical composition comprising a therapeutically effective amount of a conditioned medium derived from neonatal cardiac stem cells exposed to one or more heat shock response inducers in a culture medium in vitro, wherein the neonatal cardiac stem cells have been sorted for c-kit+ and expanded in vitro and have the following characteristics:
- c-kit+, CD90+, CD44+, CD105+, CD31−, CD34−, CD45−, Nkx2.5+, tryptase negative, and SSEA4−.
A method of treating a cardiac medical condition in a subject in need thereof, comprising administering to the subject a composition comprising human, neonatal cardiac stem cells and one or more pharmaceutically acceptable carriers, wherein the human, neonatal cardiac stem cells:
- (a) are positive for protein expression of c-kit and Nkx2.5, and
- (b) negative for protein expression of GATA4, CD31, and Isl1,
- whereby the cardiac medical condition is treated.
A method of treating a cardiac medical condition in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a human, neonatal cardiac stem cell (nCSC) secretome and a pharmaceutically acceptable carrier;
- wherein the secretome comprises SOD2, HSPA8, HSP90AA1, HSP90AB1, and HNRNPA2B1;
- whereby the cardiac medical condition is treated.
Dependencies are inferred from the claim text.